Fig. 5: Inhibition of SARS-CoV-2 in primary HNEpCs and HBEpCs by the identified natural compounds.
From: Fluorogenic reporter enables identification of compounds that inhibit SARS-CoV-2
a, Experimental procedure. b,c, Immunofluorescence staining of SARS-CoV-2 in primary HNEpCs (b) and HBEpCs (c) treated with gamabufotalin, bruceine A or anisomycin at 2 μM (b) or 50 nM (c). MOI = 3 for HNEpCs, MOI = 1 for HBEpCs. Scale bars, 50 μm (b) and 100 μm (c). d,e, Quantification of nucleocapsid-positive (N+) or spike-positive (S+) cells. HNEpCs (d) and HBEpCs (e) were immunostained with N or S, respectively. Numbers of N+ or S+ cells per 100 cells were quantified. Rectangles bordered by dashed grey lines represent samples treated with the same compound at different concentrations. Data presented as mean ± s.d. (n = 3). P values, two-sided nonpaired t-test between compound- and DMSO-treated groups. *P < 0.05, **P < 0.01. Exact P values: d, starting from gamabufotalin anti-N: 0.0023, 0.0042, 0.0027; starting from gamabufotalin anti-S: 0.0016, 0.0030, 0.0019; e, starting from gamabufotalin anti-N: 0.0045, 0.0030, 0.0030, 0.018, 0.0056, 0.0030, 0.013, 0.0035, 0.0030; starting from gamabufotalin anti-S: 0.0030, 0.0020, 0.0020, 0.013, 0.0040, 0.0020, 0.0088, 0.0023, 0.0019.
